BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15339059)

  • 1. Pemetrexed: its promise in treating non-small-cell lung cancer.
    Manegold C
    Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):43-8. PubMed ID: 15339059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of phase I/II pemetrexed studies.
    Hanauske AR; Dittrich C; Otero J
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):18-25. PubMed ID: 15655932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer.
    Scagliotti GV; Novello S; Crino L; Rosell R
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):32-7. PubMed ID: 15655934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed in advanced NSCLC: a review of the clinical data.
    Zinner RG; Fossella FV; Herbst RS
    Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):54-62. PubMed ID: 15339061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed in second-line treatment of non-small-cell lung cancer.
    De Marinis F; De Petris L
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):38-42. PubMed ID: 15655935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
    Bunn PA
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):17-22. PubMed ID: 12094334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
    Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
    Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
    Joerger M; Omlin A; Cerny T; Früh M
    Curr Drug Targets; 2010 Jan; 11(1):37-47. PubMed ID: 19839929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed in advanced colorectal cancer.
    Louvet C; de Gramont A
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD; Dragnev KH; Rigas JR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed combination therapy in the treatment of non-small cell lung cancer.
    Rosell R; Crinó L
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):23-9. PubMed ID: 12023789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.